|
|
 |
|
Viewing report
|
|
|
ALEXION - Great Expectations From Label Expansion
MP Advisors, Sep 2011
We have a positive expectation for the approval of Eculizumab (L, Soliris, Paroxysmal Nocturnal Hemoglobinuria) in Atypical Hemolytic Uremic Syndrome (aHUS, PDUFA on October 7th). Recent data presented in Myasthenia Gravis (MG) shows potential of eculizumab in other indications targeting rare and high unmet need along with robust growth opportunity in approved indication.
|
|
|
|
